Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of either sex~* Aged 40 and over~* Outpatients~* Patients fulfilling the American Congress of Rheumatology (ACR) criteria for the reporting of hand OA~* Patients showing X-ray features of hand OA on at least two joints (2 IP and/or 1 IP and 1 TMC) of the dominant hand on standard plain radiographs (\< 6 month).~* Suffering from regular spontaneous pain on the dominant hand (VAS \> or = 40 mm at inclusion time).~* Showing a FIHOA score \> or = 6.~* Having had at least two painful flares in a finger joint during the previous 12 month.~* Patients who have signed the written informed consent for their participation in the study~* Patients able to understand and follow the protocol.~* Patients with a satisfying health and nutritional status.~* Female subjects of childbearing potential using, within three months prior to the inclusion in the study, a reliable form of contraception during the course of the study (oral contraceptive pill, intrauterine device or condoms) or female of non childbearing potential (hysterectomy, bilateral ovariectomy or tubal section/ligation).~* Female subjects of childbearing potential with a negative urinary pregnancy test before the inclusion in the study.~Exclusion Criteria:~* Inflammatory joint disease of other origin~* Septic arthritis~* Chronic inflammatory joint disease~* Previous articular fracture of the concerned articulations~* Use of analgesic therapy for other indications~* Receiving oral corticosteroids~* Mono-articular posttraumatic OA of the finger~* Planning surgery of the hands in the following 6 months~* Patients suffering or having suffered from secondary osteoarthritis after one of the following diseases:~  * Infectious arthritis - Acromegaly~ * Ochronosis - Hemachromatosis~ * Gout - Wilson's disease~ * Chondrocalcinosis - Paget's disease~ * Osteochondrosis - Mutation of collagen~ * Genetic problems (for ex. hypermobility) - Previous joint fracture~ * Arthropathies of different aetiologies - Algodystrophy (M. Sudeck)~* Congenital abnormalities~* Recurrent pseudogout~* Major dysplasias~* Intra-articular injection in a hand joint from less than 3 months~* Basic treatment of arthritis with symptom-modifying agents (chondroitin sulfate, glucosamine sulfate, diacerhein, hyaluronic acid) in the last 3 months~* Articular lavage in the last 3 months~* Treatment with corticoids, by any administration route during the last month~* Patient suffering from frequent asthma crises~* Physiotherapy, re-education, alternative medicine (mesotherapy, acupuncture) on the hands foreseeable in the next year~* Serious organic diseases: heart failure, renal or hepatic insufficiency, blood dyscrasia, serious infection~* Participation in other clinical trials in the two months preceding the study~* Known or ascertained hypersensitivity to the active ingredient of the tested drug.~* Patients refusing to sign the written informed consent form~* Patients who do not co-operate, not respecting the protocol requirements~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chondroitin 4&6 sulfate (Condrosulf) (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete